Trastuzumab, a recombinant humanized monoclonal antibody directed against the human HER2 receptor tyrosine kinase, mediates tumor-killing partially by inducing antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2 overexpressing tumor cells. The gene discussed is NTRK1; the disease is neoplasm.